Meta AI Soars to Nearly 1 Billion Monthly Users

Published 1 days agoMETA

Meta AI Soars to Nearly 1 Billion Monthly Users

Meta's AI assistant has witnessed remarkable growth, amassing close to 1 billion monthly active users across its suite of apps. Launched in September 2023, the assistant swiftly became part of Facebook, Instagram, WhatsApp, Messenger, and a dedicated web app, which played a crucial role in its rapid uptake, according to a report by Moneycontrol.

By August 2024, Meta AI had already surpassed 400 million monthly active users, with about 185 million interacting on a weekly basis, as reported by The Information. In early 2025, CEO Mark Zuckerberg was optimistic about reaching more than 1 billion users by the year's end, rising from last year’s 600 million monthly figures noted by Indian Express.

On the strategic front, Meta has planned to invest up to $65 billion in AI infrastructure throughout 2025. This includes building expansive data centers and utilizing Nvidia's AI chips, with a target of deploying over 1.3 million graphics processors by the year's end, Reuters reported. To bolster revenue, Meta is exploring the introduction of a premium AI tier and embedding ads, further positioning its AI as a formidable rival to the likes of OpenAI's ChatGPT and Google’s Gemini.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Deutsche Bank Reaffirms Buy Rating on UnitedHealth Amid Positive Earnings

Deutsche Bank Reaffirms Buy Rating on UnitedHealth Amid Positive Earnings

6 minutes agoUNH

Deutsche Bank has reaffirmed its "Buy" rating on UnitedHealth Group, setting a price target at $625. This stance is fueled by what Deutsche Bank views as the company's attractive valuation. Positive earnings performance has played a significant role in bolstering this outlook, with UnitedHealth recently surpassing earnings expectations, further strengthening investors' confidence, as noted by Investing.com. Adding to the optimism, a recent legal development could potentially benefit UnitedHealth. A special master has recommended dismissing a Department of Justice lawsuit that alleged the company overbilled Medicare. This recommendation could remove a looming financial uncertainty for UnitedHealth, thus enhancing its financial stability. Beyond Deutsche Bank, other analysts are also expressing confidence in UnitedHealth. Firms like Piper Sandler and Bernstein SocGen Group have maintained positive ratings for the insurance giant, which suggests strong analyst consensus regarding the company's solid prospects moving forward.

Pfizer's BRAFTOVI Gains FDA Approval for Colorectal Cancer Treatment

Pfizer's BRAFTOVI Gains FDA Approval for Colorectal Cancer Treatment

51 minutes agoPFE

Pfizer's BRAFTOVI® (encorafenib) has reached an important milestone in the fight against metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The U.S. Food and Drug Administration (FDA) granted accelerated approval for BRAFTOVI in combination with cetuximab and mFOLFOX6 in December 2024, specifically for treatment-naïve patients. This decision was based on a significant improvement in the confirmed objective response rate (ORR). The positive Phase 3 BREAKWATER trial results have reinforced the benefits of Pfizer’s combination therapy. The regimen achieved a remarkable 61% ORR, which is a significant increase compared to the 40% seen with standard chemotherapy, according to BioSpace. Additionally, the combination demonstrated a notable improvement in progression-free survival (PFS), and an interim analysis pointed to a promising trend in overall survival, indicating a 53% reduction in the risk of death compared to chemotherapy. Pfizer reports that the safety profile of BRAFTOVI, when used with cetuximab and mFOLFOX6, is consistent with known safety profiles of these drugs, without introducing new safety concerns. These developments highlight the combination's potential to enhance patient outcomes and possibly establish a new treatment benchmark for those with BRAF V600E-mutant mCRC.

Regeneron Shares Fall After Mixed Results in COPD Drug Trials

Regeneron Shares Fall After Mixed Results in COPD Drug Trials

1 hours agoREGN

Regeneron Pharmaceuticals saw a decline in its shares by 9% following the release of mixed results from late-stage trials of its experimental drug, itepekimab. This drug, developed in collaboration with Sanofi, is aimed at treating chronic obstructive pulmonary disease (COPD). Reuters reported on the trials, with one study of 1,127 patients showing a 27% reduction in disease flare-ups over 52 weeks compared to a placebo. However, a second study did not meet its primary endpoint, casting doubt on the drug's approval prospects. The market reacted to this news, with Regeneron's stocks trading at $549.69, reflecting a 15% decline this year so far. Sanofi's shares also dipped nearly 5% in premarket trading. Analysts express skepticism about the drug's path forward, with Emily Field from Barclays hinting at the challenge of securing approval with these results, and Richard Vosser from J.P. Morgan suggesting that further studies may be needed. Itepekimab aims to counteract inflammation by inhibiting the interleukin-33 protein, a factor in COPD. The drug was anticipated to reach up to $5 billion in peak annual sales, potentially addressing a larger patient market than Dupixent, another treatment by Regeneron and Sanofi that's already approved for COPD. Following the trials' outcomes, it seems Dupixent will maintain its position as the go-to treatment.

Waste Management Stock Hits All-Time High as Confidence Grows

Waste Management Stock Hits All-Time High as Confidence Grows

Waste Management's stock is making headlines as it achieves a new all-time high, trading at $239.30 as of May 30, 2025. This marks a milestone for the company, highlighting its robust market performance and investor confidence. The stock saw a slight increase of $1.54 from the previous close, with the intraday high hitting $239.30 and the low at $237.00. Contributing to this upward momentum, the Royal Bank of Canada has recently boosted its price target for Waste Management to $229.00 from $227.00, as reported by American Banking News. In addition to favorable analyst updates, the company has posted impressive financial numbers, with a 13% revenue increase and a 21% rise in net income in the fourth quarter of 2024. Overall, for the year 2024, revenues were up by 8%, with net income climbing by 19%, and free cash flow soaring by 22%, reinforcing investor optimism. Strategically, Waste Management has been on the move, acquiring Stericycle for $7.2 billion in November 2024 to bolster its presence in medical waste management. In December 2024, the company announced a 10% dividend increase, continuing its tradition of 22 consecutive years of dividend growth. These strategic initiatives and strong financials underpin the company's impressive stock performance.